Rigel Pharmaceuticals Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Rigel Pharmaceuticals Inc. - overview
Established
1996
Location
San Francisco, CA, US
Primary Industry
Biotechnology
About
Rigel Pharmaceuticals Inc. is a biotechnology company dedicated to developing and commercializing innovative therapies for patients suffering from hematologic disorders and cancer. Founded in 1996 by Tullio Favretto, Rigel Pharmaceuticals, Inc. is headquartered in San Francisco, US.
The company specializes in therapies for hematologic conditions and cancer, having successfully raised USD 130 mn in a PIPE funding round on May 1, 2011. Rigel has engaged in three significant deals to date. Rigel Pharmaceuticals, Inc. focuses on the development and commercialization of innovative therapies for patients with hematologic disorders and cancer.
The company's primary product offerings include TAVALISSE® (fostamatinib), a tablet indicated for the treatment of adults with chronic immune thrombocytopenia, and GAVRETO® (pralsetinib), designed to treat patients with RET fusion-positive non-small cell lung cancer. Additionally, Rigel has developed REZLIDHIA® (belantamab mafodotin), which targets specific pathways involved in hematologic malignancies. These products are primarily aimed at oncologists and hematologists, serving patients across North America and select international markets, including Europe and Asia. Rigel's commitment is to enhance patient outcomes by providing targeted therapies that address unmet medical needs, particularly in complex diseases.
In the most recent fiscal year of 2024, Rigel Pharmaceuticals reported revenue of USD 144. 90 mn and an EBITDA of USD 26. 42 mn. The company generates revenue through the sale of its proprietary therapies, focusing on direct-to-consumer and business-to-business transactions with healthcare providers and institutions.
Rigel's flagship products, including TAVALISSE® and GAVRETO®, are integral to its revenue model, capitalizing on the growing demand for specialized treatment options in oncology and hematology. Rigel Pharmaceuticals plans to leverage its most recent funding of USD 130 mn raised in May 2011 to support the development and launch of new products targeting hematologic disorders and cancer. The company is actively exploring expansion into new geographic markets, specifically targeting Europe and Asia by 2024. These strategic initiatives are aimed at enhancing patient access to their innovative therapies and addressing unmet medical needs within these markets.
Current Investors
New Enterprise Associates
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Diagnostic, Medical & Imaging Laboratories, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.rigel.com
Total Amount Raised
Subscriber access only
Rigel Pharmaceuticals Inc. - timeline of key events
Rigel Pharmaceuticals Inc. - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 4,750,000 | 2,250,000 | 7,150,000 | 8,250,000 | 28,895,000 | 20,383,000 | 4,484,000 | 44,509,000 | 59,288,000 | 108,621,000 | 149,236,000 | 120,242,000 | - | - | - |
| % Revenue Growth (YoY) | - | (52.6%) | 217.8% | 15.4% | 250.2% | (29.5%) | (78.0%) | 892.6% | 33.2% | 83.2% | 37.4% | (19.4%) | - | - | - |
| EBITDA (USD) | (84,413,000) | (96,944,000) | (86,877,000) | (88,890,000) | (50,304,000) | (68,685,000) | (79,501,000) | (72,855,000) | (68,408,000) | (28,267,000) | (11,334,000) | (54,615,000) | - | - | - |
| Operating Income (USD) | (86,368,000) | (99,377,000) | (89,469,000) | (91,249,000) | (51,743,000) | (69,741,000) | (79,616,000) | (72,683,000) | (69,091,000) | (28,973,000) | (12,496,000) | (55,550,000) | - | - | - |
| Operating Margin | (1818.3%) | (4416.8%) | (1251.3%) | (1106.0%) | (179.1%) | (342.2%) | (1775.6%) | (163.3%) | (116.5%) | (26.7%) | (8.4%) | (46.2%) | - | - | - |
| % EBITDA Margin | (1777.1%) | (4308.6%) | (1215.1%) | (1077.5%) | (174.1%) | (337.0%) | (1773.0%) | (163.7%) | (115.4%) | (26.0%) | (7.6%) | (45.4%) | - | - | - |
| NET Income (USD) | (85,973,000) | (98,840,000) | (89,027,000) | (90,908,000) | (51,464,000) | (69,216,000) | (77,992,000) | (70,480,000) | (66,894,000) | (29,744,000) | (17,914,000) | (58,573,000) | - | - | - |
| % Net Margin | (1810.0%) | (4392.9%) | (1245.1%) | (1101.9%) | (178.1%) | (339.6%) | (1739.3%) | (158.3%) | (112.8%) | (27.4%) | (12.0%) | (48.7%) | - | - | - |
Rigel Pharmaceuticals Inc. - employee data
Rigel Pharmaceuticals Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Member of the Board of Directors | BM | ||||||
| Chairman of the Board | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.